Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas.
Raman spectroscopy
follicular adenoma
follicular carcinoma
immunohistochemistry
molecular markers
mutational analysis
thyroid
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
29 Dec 2020
29 Dec 2020
Historique:
received:
09
12
2020
revised:
22
12
2020
accepted:
23
12
2020
entrez:
1
1
2021
pubmed:
2
1
2021
medline:
2
1
2021
Statut:
epublish
Résumé
Follicular patterned nodules are sometimes complex to be classified due to ambiguous nuclear features and/or questionable capsular or vascular invasion. In this setting, there is a poor inter-observer concordance even among expert pathologists. Raman spectroscopy was recently used to separate benign and malignant thyroid nodules based on their molecular fingerprint; anyway, some histologically proved follicular adenomas were clustered as having a characteristic profile of malignant lesions. In this study, we analyzed five follicular thyroid adenomas with a malignant spectroscopic profile compared to five follicular adenomas with a benign Raman spectrum in order to assess possible molecular differences between the two groups. Morphological, immunohistochemical, and molecular analyses evidenced expression of malignancy-associated proteins in four out of five malignant clustered adenomas. The remaining malignant clustered adenoma showed a
Identifiants
pubmed: 33383892
pii: diagnostics11010043
doi: 10.3390/diagnostics11010043
pmc: PMC7823803
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Ministry of Health
ID : TIRAMA project (RF-2018-12366568)
Références
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068
pubmed: 29615459
Nat Commun. 2017 Jun 05;8:15533
pubmed: 28580939
Endocr Relat Cancer. 2003 Dec;10(4):591-600
pubmed: 14713269
Photodiagnosis Photodyn Ther. 2013 Sep;10(3):207-19
pubmed: 23993846
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Endocrine. 2014 May;46(1):52-9
pubmed: 24197803
Oncol Lett. 2017 Oct;14(4):4183-4189
pubmed: 28943926
Mod Pathol. 2018 Jan;31(1):39-55
pubmed: 29052599
Endocrine. 2020 Aug;69(2):451-455
pubmed: 32506194
Oncotarget. 2016 Oct 25;7(43):69638-69648
pubmed: 27626165
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Am Coll Radiol. 2017 May;14(5):587-595
pubmed: 28372962
Anal Bioanal Chem. 2015 Nov;407(27):8263-4
pubmed: 26362157
Thyroid. 2000 Nov;10(11):1009-12
pubmed: 11128715
Endocrine. 2020 May;68(2):458-465
pubmed: 32232767
Oncotarget. 2017 Jul 25;8(30):49421-49442
pubmed: 28472764
Eur Thyroid J. 2017 Jul;6(3):115-129
pubmed: 28785538
Oncol Rep. 2018 Dec;40(6):3359-3369
pubmed: 30272326
Endocrine. 2018 Nov;62(2):492-495
pubmed: 29700698
Anal Chem. 2018 Jan 2;90(1):847-854
pubmed: 29227640
Thyroid. 2020 Jun;30(6):931-935
pubmed: 32111150
Sci Rep. 2016 Oct 11;6:35117
pubmed: 27725756
Sci Rep. 2020 Aug 7;10(1):13342
pubmed: 32770073
Biomark Insights. 2017 Mar 30;12:1177271917701126
pubmed: 28469401